{
    "id": "clinical_knowledge-073",
    "question": "When using an inhaler, when should a patient be asked to rinse their mouth?",
    "options": {
        "A": "Before using their bronchodilator inhaler.",
        "B": "After using their bronchodilator inhaler.",
        "C": "Before using their steroid inhaler.",
        "D": "After using their steroid inhaler."
    },
    "answer": "D",
    "predict": "{\"step_by_step_thinking\": \"To determine the correct answer, we need to consider the purpose of rinsing the mouth when using an inhaler, especially in the context of asthma treatment. The primary concern is to prevent oral candidiasis (thrush), a fungal infection that can be caused by the presence of inhaled corticosteroids (ICS) and other medications. This is because ICS can suppress the immune system, making it easier for fungi to grow. The question is about when to ask the patient to rinse their mouth, which is crucial for preventing oral candidiasis. Rinsing the mouth before using the inhaler would not make sense, as the patient has not yet inhaled the medication. Similarly, rinsing after using the steroid inhaler would also not be the best approach, as the patient has already inhaled the medication. The correct answer is to ask the patient to rinse their mouth after using their bronchodilator inhaler, as this is when the medication is most likely to be in contact with the oral mucosa, increasing the risk of oral candidiasis. This approach helps to minimize the risk of oral complications and ensures the effectiveness of the inhaler treatment.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_20168",
            "title": "InternalMed_Harrison",
            "content": "A high concentration of oxygen should be given by face mask to achieve oxygen saturation of >90%. The mainstay of treatment are high doses of SABA given either by nebulizer or via a metered-dose inhaler with a spacer. In severely ill patients with impending respiratory failure, IV \u03b22-agonists may be given. A nebulized anticholinergic may be added if there is not a satisfactory response to \u03b22-agonists alone, as there are additive effects. In patients who are refractory to inhaled therapies, a slow infusion of aminophylline may be effective, but it is important to monitor blood levels, especially if patients have already been treated with oral theophylline. Magnesium sulfate given intravenously or by nebulizer is effective when added to inhaled \u03b22-agonists, and is relatively well tolerated but is not routinely recommended. Prophylactic intubation may be indicated for impending respiratory failure, when the PCO2 is normal or rises. For patients with respiratory failure, it is necessary"
        },
        {
            "id": "InternalMed_Harrison_20164",
            "title": "InternalMed_Harrison",
            "content": "an add-on therapy, but these are less effective than LABA. In patients with severe asthma, low-dose oral theophylline is also helpful, and when there is irreversible airway narrowing, the long-acting anticholinergic tiotropium bromide may be tried. If asthma is not controlled despite the maximal recommended dose of inhaled therapy, it is important to check compliance and inhaler technique. In these patients, maintenance treatment with an OCS may be needed, and the lowest dose that maintains control should be used. Occasionally omalizumab may be tried in steroid-dependent asthmatics who are not well controlled. Once asthma is controlled, it is important to slowly decrease therapy in order to find the optimal dose to control symptoms."
        },
        {
            "id": "Pediatrics_Nelson_2904",
            "title": "Pediatrics_Nelson",
            "content": "Delivering therapeutic agents to the lower respiratory tract can be accomplished by inhalation of aerosol forms of the agents via dry powder inhaler (DPI), metered dose inhaler (MDI), or nebulizer. All of these devices are designed to generate relatively small particles that can bypass the filtering action of the upper airway and deposit in the lower airways. Many factors influence drug deposition, including patient technique, device used, age of the child, and breathing pattern. Nebulizers should be used with a face mask (infants) or mouthpiece (children and teens) to minimize loss of drug to ambient air. Plastic holding chambers (spacers) are available for all ages and should always be used with MDIs. Dry powder inhalers require a single rapid deep inhalation for optimal drug delivery, which is difficult for children under 6 years of age. MDIs and nebulizers are equally effective in delivering medications only if the technique is correct, so it is important to review this frequently"
        },
        {
            "id": "InternalMed_Harrison_31964",
            "title": "InternalMed_Harrison",
            "content": "All patients should be asked whether they smoke, how much they smoke, how long they have smoked, their past experience with quitting, and whether they are currently interested in quitting. Intensity of smoking and smoking within 30 min of waking are useful measures of the intensity of nicotine addiction. Even those who are not interested in quitting should be encouraged and motivated to quit; provided a clear, strong, and personalized message by the clinician that smoking Ask: Systematically identify all tobacco users at every visit Advise: Strongly urge all smokers to quit Identify smokers willing to quit Assist the patient in quitting Arrange follow-up contact First-line therapies Nicotine gum (1.5) Nicotine patch (1.9) Nicotine nasal inhaler (2.7) Nicotine oral inhaler (2.5) Nicotine lozenge (2.0) Bupropion (2.1) Varenicline (2.7) Second-line therapies Clonidine (2.1) Nortriptyline (3.2) Physician or other medical personnel counseling (10 min) (1.3)"
        },
        {
            "id": "InternalMed_Harrison_2487",
            "title": "InternalMed_Harrison",
            "content": "Proper oral and nasal hygiene and routine dental care are extremely important ways for patients to protect themselves from disorders of the mouth and nose that can ultimately result in chemosensory disturbance. Patients should be warned not to overcompensate for their taste loss by adding excessive amounts of sugar or salt. Smoking cessation and the discontinuance of oral tobacco use are essential in the management of any patient with smell and/or taste disturbance and should be repeatedly emphasized."
        },
        {
            "id": "Pharmacology_Katzung_2862",
            "title": "Pharmacology_Katzung",
            "content": "the patient\u2019s larynx and vocal cords and cannot successfully pass an endotracheal tube. You switch to mask ventilation but are barely able to mask ventilate the patient, and you become worried that you will soon lose the ability to ventilate at all. Is there a medication that you can give to facilitate rapid return of spontaneous ventilation in this situation?"
        },
        {
            "id": "Pharmacology_Katzung_2047",
            "title": "Pharmacology_Katzung",
            "content": "Joshua M. Galanter, MD, & Homer A. Boushey, MD and respirations are 32/min. Her mother states that she has used her albuterol inhaler several times a day for the past 3 days and twice during the previous night. She took an additional two puffs on her way to the emergency department, but her mother states that \u201cthe inhaler didn\u2019t seem to be helping so I told her not to take any more.\u201d What emergency measures are indicated? How should her long-term management be altered? A 14-year-old girl with a history of asthma requiring daily inhaled corticosteroid therapy and allergies to house dust mites, cats, grasses, and ragweed presents to the emergency department in mid-September, reporting a recent \u201ccold\u201d com-plicated by worsening shortness of breath and audible inspi-ratory and expiratory wheezing. She appears frightened and refuses to lie down but is not cyanotic. Her pulse is 120 bpm,"
        },
        {
            "id": "Pediatrics_Nelson_1794",
            "title": "Pediatrics_Nelson",
            "content": "Key: DPI, Dry power inhaler; HFA, hydrofluoroalkane; MDI, metered-dose inhaler; NA, not available (either not approved, no data available, or safety and efficacy not established for this age group) Therapeutic Issues: \u007f The most important determinant of appropriate dosing is the clinician\u2019s judgment of the patient\u2019s response to therapy. The clinician must monitor the patient\u2019s response on several clinical parameters and adjust the dose accordingly. Once control of asthma is achieved, the dose should be carefully titrated to the minimum dose required to maintain control. \u007f Preparations are not interchangeable on a \u00b5g or per puff basis. This figure presents estimated comparable daily doses. See EPR\u20133 Full Report 2007 for full discussion. \u007f Some doses may be outside package labeling, especially in the high-dose range. Budesonide nebulizer suspension is the only inhaler corticosteroid (ICS) with FDAapproved labeling for children <4 years of age."
        },
        {
            "id": "Neurology_Adams_1807",
            "title": "Neurology_Adams",
            "content": "is spit out and the mouth rinsed with water. The patient indicates whether a taste was detected and then is asked to try to identify it. Special types of apparatus (electrogustometers) have been devised for the measurement of taste intensity and for determining the detection and recognition thresholds of taste and olfactory stimuli (Krarup; Henkin et al), but these are beyond the needs of the usual clinical examination."
        },
        {
            "id": "Pediatrics_Nelson_1778",
            "title": "Pediatrics_Nelson",
            "content": "Step up if needed (first check inhaler technique, adherence, environmental control, and comorbid conditions) Step down if possible (and asthma is well controlled at least 3 months)"
        },
        {
            "id": "Pediatrics_Nelson_1808",
            "title": "Pediatrics_Nelson",
            "content": "to severe asthma, or have a history of severe exacerbations. Peak flow monitoring also can be useful in children who are still learning to recognize asthma symptoms. To use a peak flow meter, a child should be standing with the indicator placed at the bottom of the scale. The child must inhale deeply, place the device in the mouth, seal the lips around the mouthpiece, and blow out forcefully and rapidly. The indicator moves up the numeric scale. The PEFR is the highest number achieved. The test is repeated three times to obtain the best possible effort. Peak flow meters are available as low range (<300 L/sec) and high range (<700 L/sec). It is important to provide the appropriate range meter so that accurate measurements can be obtained and children do not become discouraged because their exhalations barely move the indicator."
        },
        {
            "id": "Pediatrics_Nelson_1782",
            "title": "Pediatrics_Nelson",
            "content": "If clear benefit is not observed within 4\u20136 weeks, and patient\u2019s/family\u2019s medication technique and adherence are satisfactory, consider adjusting therapy or an alternative diagnosis. \u007f Studies on children 0\u20134 years of age are limited. Step 2 preferred therapy is based on Evidence A. All other recommendations are based on expert opinion and extrapolation from studies in older children. \u007f Clinicians who administer immunotherapy should be prepared and equipped to identify and treat anaphylaxis that may occur. Key: Alphabetical listing is used when more than one treatment option is listed within either preferred or alternative therapy. ICS, Inhaled corti-costeroid; LABA, inhaled long-acting beta2-agonist; LTRA, leukotriene receptor antagonist, oral corti-costeroids, oral systemic corticosteroids; SABA, inhaled short-acting beta2-agonist \u007f The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs. \u007f If an"
        },
        {
            "id": "InternalMed_Harrison_20163",
            "title": "InternalMed_Harrison",
            "content": "Stepwise Therapy For patients with mild, intermittent asthma, a short-acting \u03b22-agonist is all that is required (Fig. 309-8). However, use of a reliever medication more than twice a week indicates the need for regular controller therapy. The treatment of choice for all patients is an ICS given twice daily. It is usual to start with an intermediate dose (e.g., 200 \u03bcg bid of beclomethasone dipropionate [BDP]) or equivalent and to decrease the dose if symptoms are controlled after 3 months. If symptoms are not controlled, a LABA should be added, which is most conveniently given by switching to a combination inhaler. The dose of controller should be adjusted accordingly, as judged by the need for a rescue inhaler. Low doses of theophylline or an antileukotriene may also be considered as an add-on therapy, but these are less effective than LABA. In patients with severe asthma, low-dose oral theophylline is also helpful, and when there is irreversible airway narrowing, the long-acting"
        },
        {
            "id": "InternalMed_Harrison_20177",
            "title": "InternalMed_Harrison",
            "content": "Refractory asthma is difficult to control, by definition. It is important to check compliance and the correct use of inhalers and to identify and eliminate any underlying triggers. Low doses of theophylline may be helpful in some patients, and theophylline withdrawal has been found to worsen in many patients. Most of these patients will require maintenance treatment with oral corticosteroids, and the minimal dose that achieves satisfactory control should be determined by careful dose titration. Steroid-sparing therapies are rarely effective. In some patients with allergic asthma, omalizumab is effective, particularly when there are frequent exacerbations. Anti-TNF therapy is not effective in severe asthma and should not be used. A few patients may benefit from infusions of \u03b22-agonists. New therapies are needed for these patients, who currently consume a disproportionate amount of health care spending."
        },
        {
            "id": "InternalMed_Harrison_20445",
            "title": "InternalMed_Harrison",
            "content": "Patients are often treated initially with nebulized therapy, as such 1707 treatment is often easier to administer in older patients or to those in respiratory distress. It has been shown, however, that conversion to metered-dose inhalers is effective when accompanied by education and training of patients and staff. This approach has significant economic benefits and also allows an easier transition to outpatient care. The addition of methylxanthines (such as theophylline) to this regimen can be considered, although convincing proof of its efficacy is lacking. If added, serum levels should be monitored in an attempt to minimize toxicity."
        },
        {
            "id": "Pediatrics_Nelson_1806",
            "title": "Pediatrics_Nelson",
            "content": "Add: mg per day. For (3\u201310) days (oral corticosteroid) the doctor hours after taking the oral corticosteroid.(phone) Medical Alert! Take this medicine: Very short of breath, or Nebulizer Quick-relief medicines have not helped, or (short-acting beta2-agonist) Cannot do usual activities, or mg Symptoms are same or get worse after (oral corticosteroid) 24 hours in Yellow Zone. Then call your doctor NOW. Go to the hospital or call an ambulance if You are still in the red zone after 15 minutes AND Peak flow: less than You have not reached your doctor. (50 percent of my best peak flow) Trouble walking and talking due to shortness of breath puffs of your quick-relief medicine 6AND Lips or fingernails are blue Go to the hospital or call for an ambulance NOW! Allergy Atopic dermatitis Allergic rhinitis Elevated total serum IgE levels (first year of life) Peripheral blood eosinophilia >4% (2\u20133 yr of age) Food and inhalant allergen sensitization"
        },
        {
            "id": "Surgery_Schwartz_4289",
            "title": "Surgery_Schwartz",
            "content": "secondary to direct contact (e.g., buccal mucosa) as well as subsites with depen-dent saliva drainage (e.g., floor of mouth, mandibular alveolus, and wet lip). Reverse smoking, where the lighted portion of the tobacco product is placed within the mouth during inhalation is also associated with oral cavity cancer, specifically hard palate carcinoma. The risk for this cancer is 47 times greater in patients that exhibit this behavior compared to nonsmokers.78In Europe and North America there has been an increas-ing interest in decriminalizing marijuana smoking. There is a strong correlation between this activity and head and neck can-cers (OR 2.5; 95% CI 1.1\u20136.6) when compared to nonusers.79 Furthermore, there is a dose-response relationship that is stron-ger in young patients (55 years of age or less). Ultraviolet light VermilionBuccal mucosaHard palateSoft palateRetromolar trigoneCircumvallate papillaeLower gingivaPalatine raphePalatine tonsilFigure 18-20. Oral cavity"
        },
        {
            "id": "InternalMed_Harrison_20165",
            "title": "InternalMed_Harrison",
            "content": "Education Patients with asthma need to understand how to use their medications and the difference between reliever and controller FIGURE 309-8 Stepwise approach to asthma therapy according to the severity of asthma and ability to control symptoms. ICS, inhaled corticosteroids; LABA, long-acting \u03b22-agonist; OCS, oral corticosteroid. therapies. Education may improve compliance, particularly with ICS. 1679 All patients should be taught how to use their inhalers correctly. In particular, they need to understand how to recognize worsening of asthma and how to step up therapy. Written action plans have been shown to reduce hospital admissions and morbidity rates in adults and children, and are recommended particularly in patients with unstable disease who have frequent exacerbations."
        },
        {
            "id": "Obstentrics_Williams_3361",
            "title": "Obstentrics_Williams",
            "content": "Inhaled luid should be immediately and thoroughly wiped from the mouth and removed from the pharynx and trachea by suction. Saline lavage may further disseminate the acid throughout the lung and is not recommended. If large particulate matter is inspired, bronchoscopy may be indicated to relieve airway obstruction. No convincing evidence supports that corticosteroid therapy or prophylactic antimicrobial administration is beneicial (Marik, 2001). If infection develops, however, then vigorous treatment is given. If acute respiratory failure develops, mechanical ventilation with positive end-expiratory pressure may be lifesaving (Chap. 47, p. 919)."
        },
        {
            "id": "Pediatrics_Nelson_1763",
            "title": "Pediatrics_Nelson",
            "content": "Inhaled corticosteroids are the most effective anti-inflammatory medications for the treatment of chronic, persistent asthma and are the preferred therapy when initiating longterm control therapy. Early intervention with inhaled corticosteroids reduces morbidity but does not alter the natural history of asthma. Regular use reduces airway hyperreactivity, the need for rescue bronchodilator therapy, risk of hospitalization, and risk of death from asthma. Inhaled corticosteroids are available as an inhalation aerosol, dry powder inhaler, and nebulizer solution."
        },
        {
            "id": "Pediatrics_Nelson_1795",
            "title": "Pediatrics_Nelson",
            "content": "\u007f For children <4 years of age: The safety and efficacy of ICSs in children <1 year has not been established. Children <4 years of age generally require delivery of ICS (budesonide and fluticasone HFA) through a face mask that should fit snugly over nose and mouth and avoid nebulizing in the eyes. Wash face after each treatment to prevent local corticosteroid side effects. For budesonide, the dose may be administered 1\u20133 times daily. Budesonide suspension is compatible with Albuterol, Ipratropium, and Levalbuterol nebulizer solutions in the same nebulizer. Use only jet nebulizers, as ultrasonic nebulizers are ineffective for suspensions. For Fluticasone HFA, the dose should be divided 2 times daily; the low dose for children <4 years of age is higher than for children 5\u201311 years of age due to lower dose delivered with face mask and data on efficacy in young children. Potential Adverse Effects of Inhaled Corticosteroids: \u007f Cough, dysphonia, oral thrush (candidiasis)."
        },
        {
            "id": "InternalMed_Harrison_20423",
            "title": "InternalMed_Harrison",
            "content": "Bronchodilators In general, bronchodilators are used for symptomatic benefit in patients with COPD. The inhaled route is preferred for medication delivery because the incidence of side effects is lower than that seen with the use of parenteral medication delivery."
        },
        {
            "id": "Neurology_Adams_1806",
            "title": "Neurology_Adams",
            "content": "Unilateral gustatory impairment can be identified by withdrawing the tongue with a gauze sponge and using a moistened applicator to place a few crystals of salt, sugar, lemon (sour), and quinine (bitter) on discrete parts of the tongue; the tongue is then wiped clean and the subject is asked to report what was sensed. One use of such testing is to corroborate the existence of Bell palsy by comparing taste sensation on each side of the anterior tongue (see Chap. 44). A stimulus that has been used as a surrogate for sour sensation is a low-voltage direct current, the electrodes of which can be accurately placed on the tongue surface. If the taste loss is bilateral, mouthwashes with a dilute solution of sucrose, sodium chloride, citric acid, and quinine may be used. After swishing, the test fluid is spit out and the mouth rinsed with water. The patient indicates whether a taste was detected and then is asked to try to identify it. Special types of apparatus (electrogustometers) have been"
        },
        {
            "id": "InternalMed_Harrison_25456",
            "title": "InternalMed_Harrison",
            "content": "Avoid Smoking areas, windy, low humidity environment, drugs with anticholinergic action, diuretics Lubrication Artificial tears without preservatives, bicarbonate-buffered electrolyte solutions Oral hygiene after each meal Topical application of fluoride Lubrication Water Local stimulation Sugar-free, flavored lozenges or gum Systemic stimulation As for dry eyes Oral candidiasis Topical nystatin or clotrimazole lozenges Apply Local wet heat Treat superinfection Antibiotics, analgesics Persistent, hard Rule out lymphoma Local stimulation Cyclic adenosine mono-phosphate, cyclosporine 2% olive solution Systemic stimulation Pilocarpine (5 mg thrice daily orally); cevimeline (30 mg thrice daily orally) Severe dry eyes Nasolacrimal duct occlusion (temporary or permanent); soft contact lenses; corneal transplantation Glandular manifestations Extraglandular manifestations Parotid gland enlargement Dry mouth Dry eyes Arthritis Cold protection: gloves Raynaud\u2019s phenomenon Bicarbonate"
        },
        {
            "id": "First_Aid_Step2_1064",
            "title": "First_Aid_Step2",
            "content": "Medications for Chronic Treatment of Asthma Mild intermittent \u2264 2 days/week \u2264 2 nights/month \u2265 80% No daily medications. PRN short-acting bronchodilator. Mild persistent > 2/week but < 1/day > 2 nights/month \u2265 80% Daily low-dose inhaled corticosteroids. PRN short-acting bronchodilator. Moderate persistent Daily > 1 night/week 60\u201380% Lowto medium-dose inhaled corticosteroids + long-acting inhaled \u03b22-agonists. Severe persistent Continual, frequent \u2264 60% High-dose inhaled corticosteroids + long-acting inhaled \u03b22-agonists. Possible PO corticosteroids. PRN short-acting bronchodilator. theophylline. Montelukast and other leukotriene antagonists are oral adjuncts to inhalant therapy. A disease caused by cycles of infection and infammation in the bronchi/bronchioles that lead to permanent fbrosis, remodeling, and dilation of bronchi. Presents with chronic cough accompanied by frequent bouts of yellow or green sputum production, dyspnea, and possible hemoptysis and halitosis."
        },
        {
            "id": "Pediatrics_Nelson_1798",
            "title": "Pediatrics_Nelson",
            "content": "Figure 78-3 Estimated comparative daily dosages for inhaled corticosteroids. (From National Heart Lung Blood Institute, National Asthma Education and Prevention Program: Expert panel report 3: guidelines for the diagnosis and management of asthma. Summary report 2007, NIH Publication No. 08-5846, Bethesda, MD, 2007, U.S. Department of Health and Human Services, p 49, http://www.nhlbi.nih.gov/ guidelines/asthma/asthsumm.pdf following: allergic rhinitis, wheezing with a cold, or eosino-teaching basic asthma facts, explaining the role of medica philia of greater than 4%. Atopy is the strongest predictor for tions, teaching environmental control measures, and improv wheezing continuing into persistent asthma (Table 78-4). ing patient skills in the use of spacer devices for metered dose inhalers and peak flow monitoring. Families should have an asthma management plan (Fig. 78-5) for daily care and for PREVENTION exacerbations."
        },
        {
            "id": "Pharmacology_Katzung_2073",
            "title": "Pharmacology_Katzung",
            "content": "Albuterol, terbutaline, metaproterenol, and pirbuterol are available as metered-dose inhalers. Given by inhalation, these agents cause bronchodilation equivalent to that produced by isoproterenol. Bronchodilation is maximal within 15 minutes and persists for 3\u20134 hours. All can be diluted in saline for administration from a hand-held nebulizer. Because the particles generated by a nebulizer are much larger than those from a metered-dose inhaler, much higher doses must be given (2.5\u20135.0 mg vs 100\u2013 400 mcg) but are no more effective. Nebulized therapy should thus be reserved for patients unable to coordinate inhalation from a metered-dose inhaler."
        },
        {
            "id": "Pediatrics_Nelson_3011",
            "title": "Pediatrics_Nelson",
            "content": "7% hypertonic saline, both delivered by nebulizer, decrease the viscosity of mucus. Antibiotic therapy is important in controlling chronic infection. Monitoring pulmonary bacterial flora via airway cultures and providing aggressive therapy with appropriate antibiotics (oral, aerosolized, and IV) help to slow the progression of lung disease. Patients often require 2to 3-week courses of high-dose intravenous antibiotics and aggressive chest physiotherapy to treat pulmonary exacerbations. Antibiotics are selected based on organisms identified by sputum culture. If patients are unable to provide sputum, then a throat culture for CF pathogens can be used to direct therapy. Common infecting organisms are Pseudomonas aeruginosa and Staphylococcus aureus."
        },
        {
            "id": "InternalMed_Harrison_2474",
            "title": "InternalMed_Harrison",
            "content": "Given the various mechanisms by which olfactory and gustatory disturbance can occur, management of patients tends to be condition specific. For example, patients with hypothyroidism, diabetes, or infections often benefit from specific treatments to correct the underlying disease process that is adversely influencing chemoreception. For most patients who present primarily with obstructive/transport loss affecting the nasal and paranasal regions (e.g., allergic rhinitis, polyposis, intranasal neoplasms, nasal deviations), medical and/or surgical intervention is often beneficial. Antifungal and antibiotic treatments may reverse taste problems secondary to candidiasis or other oral infections. Chlorhexidine mouthwash mitigates some salty or bitter dysgeusias, conceivably as a result of its strong positive charge. Excessive dryness of the oral mucosa is a problem with many medications and conditions, and artificial saliva (e.g., Xerolube) or oral pilocarpine treatments may prove"
        },
        {
            "id": "InternalMed_Harrison_10229",
            "title": "InternalMed_Harrison",
            "content": "Mitigation of underlying risk factors may be the best approach to prevention of lung abscesses, with attention directed toward airway protection, oral hygiene, and minimized sedation with elevation of the head of the bed for patients at risk for aspiration. Prophylaxis against certain pathogens in at-risk patients (e.g., recipients of bone marrow or solid organ transplants or patients whose immune systems are significantly compromised by HIV infection) may be undertaken. APPROACH TO THE PATIENT:"
        },
        {
            "id": "Pharmacology_Katzung_2110",
            "title": "Pharmacology_Katzung",
            "content": "Another approach to reducing the risk of long-term, twice-daily use of ICS is to administer them only intermittently, when symptoms of asthma flare. Taking a single inhalation of an ICS with each inhalation of a short-acting \u03b2-agonist reliever (eg, an inhalation of beclomethasone for each inhalation of albuterol) or taking a 5to 10-day course of twice-daily high-dose budesonide or beclomethasone when asthma symptoms worsen has been found to be nearly as effective as regular daily therapy in adults and children with mild to moderate asthma, although these approaches to treatment are neither endorsed by guidelines for asthma management nor approved by the FDA."
        },
        {
            "id": "Surgery_Schwartz_6885",
            "title": "Surgery_Schwartz",
            "content": "pharynx, or mouth, is highly suggestive of foregut pathology. It is often particularly severe at night when supine or when bending over and can be secondary to either an incompetent or obstructed GEJ. With the latter, as in achalasia, the regurgitant is often bland, as if food was put into a blender. When questioned, most patients can distinguish the two. It is the regurgitation of gastric contents that may result in associated pulmonary symptoms, including cough, hoarseness, asthma, and recurrent pneumonia. Bronchospasm can be precipitated by esophageal acidification and cough by either acid stimulation or distention of the esophagus.Dysphagia, or difficulty swallowing, is a relatively non-specific term but arguably the most specific symptom of foregut disease. It can be a sign of underlying malignancy and should be aggressively investigated until a diagnosis is established. Dyspha-gia refers to the sensation of difficulty in the passage of food from the mouth to the stomach and can"
        }
    ],
    "scores": [
        0.029952544630525914,
        0.029425482769110105,
        0.02932029628302197,
        0.027911123963755544,
        0.027430058337691722,
        0.024113525253690496,
        0.024012251206846667,
        0.022781191726005214,
        0.021711152551056115,
        0.021620709075599008,
        0.020741189204043407,
        0.02030898226911516,
        0.020161383779574278,
        0.020145811635173337,
        0.018614718614718615,
        0.0178585665311329,
        0.01770050125313283,
        0.017028985507246377,
        0.017027417027417027,
        0.01645196908354803,
        0.01641810570381999,
        0.016234616391725583,
        0.016173348320219806,
        0.015556974516746966,
        0.015104879160966712,
        0.014756944444444444,
        0.014593576733967988,
        0.014415348716619134,
        0.014034068912117692,
        0.013928571428571429,
        0.013636363636363637,
        0.013634290925672594
    ],
    "execution_time": 31.566612482070923
}